4.7 Article

WT1 mutations in T-ALL

Journal

BLOOD
Volume 114, Issue 5, Pages 1038-1045

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2008-12-192039

Keywords

-

Categories

Funding

  1. National Institutes of Health [R01CA120196, R01CA129382, CA114737, CA02111]
  2. ECOG's Leukemia Tissue Bank
  3. WOLF Foundation
  4. Leukemia & Lymphoma Society [1287-08, 6237-08]
  5. Charlotte Geyer Foundation
  6. Cancer Research Institute
  7. Swim Across America Foundation
  8. Golfers Against Cancer Foundation
  9. Leukemia Research Fund
  10. Medical Research Council of Great Britain
  11. Fondo de Investigacion Sanitaria [CD07/00033]
  12. Leukemia & Lymphoma Society Scholar
  13. Alex's Lemonade Stand Foundation
  14. Medical Research Council [G0500389, MC_U137686856] Funding Source: researchfish
  15. National Institute for Health Research [NF-SI-0507-10370] Funding Source: researchfish
  16. MRC [G0500389, MC_U137686856] Funding Source: UKRI

Ask authors/readers for more resources

The molecular mechanisms involved in disease progression and relapse in T-cell acute lymphoblastic leukemia (T-ALL) are poorly understood. We used single nucleotide polymorphism array analysis to analyze paired diagnostic and relapsed T-ALL samples to identify recurrent genetic alterations in T-ALL. This analysis showed that diagnosis and relapsed cases have common genetic alterations, but also that relapsed samples frequently lose chromosomal markers present at diagnosis, suggesting that relapsed T-ALL emerges from an ancestral clone different from the major leukemic population at diagnosis. In addition, we identified deletions and associated mutations in the WT1 tumor suppressor gene in 2 of 9 samples. Subsequent analysis showed WT1 mutations in 28 of 211 (13.2%) of pediatric and 10 of 85 (11.7%) of adult T-ALL cases. WT1 mutations present in T-ALL are predominantly heterozygous frame-shift mutations resulting in truncation of the C-terminal zinc finger domains of this transcription factor. WT1 mutations are most prominently found in T-ALL cases with aberrant rearrangements of the oncogenic TLX1, TLX3, and HOXA transcription factor oncogenes. Survival analysis demonstrated that WT1 mutations do not confer adverse prognosis in pediatric and adult T-ALL. Overall, these results identify the presence of WT1 mutations as a recurrent genetic alteration in T-ALL. (Blood. 2009; 114: 1038-1045)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available